紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究

A clinical study on paclitaxe! plus cisplatin combined therapy in the treatment of advanced non-small cell lung cancer

目的观察紫杉醇与顺铂联合化疗治疗晚期非小细胞肺癌的近期疗效及毒副反应。方法紫杉醇135mg/m2静脉滴注d1,顺铂75mg/m2分3d静脉点滴d2-4,每21天为1周期,连用2周期。结果可评价疗效者66例,全组无CR者,总有效率(CR+PR)42.4%(28/66),其中初治者有效率53.8%(7/13),复治者有效率39.6%(21/53)。毒副反应主要是骨髓抑制、脱发和关节肌肉疼痛,其他毒副反应均较轻微可耐受。结论紫杉醇+顺铂治疗晚期非小细胞肺癌可获得较好疗效,毒副反应可以耐受,是一个较好的联合化疗方案。

Objective To evaluate the results of combined chemotherapy with paclitaxel(PTX) plus cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods From Oct. 2000 to Oct. 2003, 66 patients with advanced non- small cell lung cancer received PTX 135 mg/m2 by intravenous infusion on day 1, and DDP 75mg/m2 by intravenous infusion on day 2-4 . The treatment was repeated every 21 days, up to 2 cycles. Results 66 patients were evaluated for efficacy.28 got partial responses (42.4% ), with an overall rate of 42.4% . The main toxicities were myelosuppression, nausea and vomiting, and other side effects were mild. Conclusion A high response rate can be obtained in advanced NSCLC by PTX plus DDP. PTX is a promising antitumor agent with tolerable toxicity.